课题基金 / 基金详情

SAFETY TOLERABILITY & ANTIRETROVIRAL ACTIVITY OF DMP-266 WITH ZDV AND 3TC IN HIV

SAFETY TOLERABILITY & ANTIRETROVIRAL ACTIVITY OF DMP-266 WITH ZDV AND 3TC IN HIV
安全耐受性
批准号：
6283068
负责人：
M E EYSTER
金额：
$2.16万
依托单位：
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6283068
关键词：
AIDS therapy HIV infections antiAIDS agent clinical research combination chemotherapy drug screening /evaluation human subject lamivudine reverse transcriptase inhibitors zidovudine

项目摘要

项目成果

M E EYSTER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a double blind, placebo-controlled study to assess the safety, tolerability, and antiretroviral activity of DMP-266 in combination with open-label zidovudine (ZVD) and lamivudine (3TC) in HIV infected patients. The objectives of the study are : to evaluate the safety , tolerability and effectiveness (antiretroviral activity) of DMP-266 in combination with ZDV and 3TC in asymptomatic or mildly symptomatic HIV- infected patients; to assess the pharmacokinetics of multiple doses of DMP 266 in this patient population and to assess whether there is a pharmacokinetic interaction betweenZDV, 3TC and DMP-266; and to characterize the time course of development of resistance to DMP-266 and to characterize by genotyping and in vitro susceptibility testing strains of HIV resistant to DMP 266.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EFFECTS OF COMBINED ANTIRETROVIRAL THERAPY ON COAGULATION FACTORS
SAFETY TOLERABILITY & ANTIRETROVIRAL ACTIVITY OF DMP-266 WITH ZDV AND 3TC IN HIV
SAQUINAVIR
EFFECTS OF COMBINED ANTIRETROVIRAL THERAPY ON COAGULATION FACTORS
海外基金